Scientific deep-dive

Does Your GLP-1 Wear Off Before the Next Dose?

Half of each dose is still present when the next one is due — the label puts semaglutide's elimination half-life at roughly seven days, tirzepatide's at about five. That is a slope, not a cliff.

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
6 min read·2 citations

A lot of people say the same thing: the first few days after the injection feel different from the last few. The pharmacology does not predict a cliff. Semaglutide’s elimination half-life is about one week,[1] and tirzepatide’s is about five days[2] — on a weekly schedule that produces a gentle slope between doses, not a drop-off. So the experience is real and common, and the explanation is probably not that the drug has run out.

What a one-week half-life actually means

A half-life is the time it takes for half the drug to leave. If semaglutide’s is roughly a week and you inject weekly, then by the time the next dose is due, roughly half of the previous one is still there — and the new dose lands on top of what remains.

That is why these drugs take weeks to reach full effect at any given dose, and it is why the label says semaglutide remains in circulation for five to seven weeks after a final injection.[1] A drug that lingers for over a month is not a drug that empties out by Friday.

By the time your next dose is due, about half the last one is still working.

Tirzepatide’s five-day half-life makes its weekly swing slightly wider than semaglutide’s, which is a real difference and still a slope rather than a step. Our dose plotter draws the curve from these figures if you want to see the shape rather than read about it.

So what are people feeling?

Several things fit the pattern better than the drug disappearing, and more than one can be true at once.

  1. The side effects fade before the appetite effect does. Nausea is usually worst in the day or two after an injection. If eating was unappealing early in the week partly because you felt queasy, appetite returning later is the nausea lifting rather than the drug failing.
  2. The dose is genuinely too low for you. A dose that controls appetite for four days and not seven is a dose worth discussing — not because the drug wears off, but because the level it holds you at may be under what you need. That is a titration conversation, and it belongs with your prescriber.
  3. Expectation shapes what you notice. Once someone believes days five to seven are the hard ones, hunger on day six gets attributed to the schedule and hunger on day two does not. This is not the same as imagining it.
  4. Ordinary life is not evenly distributed across the week. Weekends, social eating, sleep debt and stress do not fall randomly, and most people inject on the same day every week — which lines those things up with the same point in the cycle every time.
The fourth one is worth sitting with. If you inject on Monday, your “day six” is always Saturday. Any weekly rhythm in your eating — and most people have one — will map perfectly onto the dosing cycle and look like pharmacology. Changing injection day for a few weeks is the cheapest way to find out, and it is a question worth putting to your prescriber rather than acting on alone.

What not to do about it

Splitting the weekly dose into two half-doses to “smooth it out” is a common suggestion online and is not something to do on your own. It changes the concentration curve, it is not how the drug was studied, and with a compounded vial it compounds an uncertainty you already have — see what is in a compounded vial.

Taking the next dose early has the same problem from the other direction. Doses landing closer together raise the level you are held at, which is a titration decision with a labeled schedule behind it. Our titration planner prints your drug’s own schedule, which is a better thing to bring to an appointment than a description of how Thursdays feel.

When it is worth raising

  • If the pattern is consistent over several weeks, that is information, and worth describing precisely: which days, what changes, how much.
  • If weight loss has genuinely stalled rather than the feeling changing, that is a different conversation with different answers.
  • If you are missing or delaying doses, the curve really does sag — our missed dose guide covers what the labels say about timing.

Frequently Asked Questions

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Section 12.3 Pharmacokinetics: elimination half-life approximately 1 week (revised 06/2026) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information: half-life of tirzepatide of approximately 5 days (SPL effective 2026-04-22) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Wegovy 7.2 mg: What the Higher Dose Actually Costs

At 7.2 mg, abnormal skin sensation was reported by 22% — against 6% at 2.4 mg and zero on placebo. Nausea barely moves. The cost of escalating is not where anyone expects it.

6 min read

How Many Units Is Your GLP-1 Dose? It Depends on the Vial

A syringe measures volume, a dose is measured in milligrams, and the number connecting them is set by whichever pharmacy filled your vial. Full conversion tables for compounded semaglutide and tirzepatide.

8 min read

Where to Inject a GLP-1, and Why Rotation Matters

Belly, thigh-front or the back of an upper arm, and always under the skin rather than into muscle. Rotation is the part people quietly drop — and dropping it can look exactly like the drug having stopped working.

6 min read

Is There a Best Time of Day to Inject a GLP-1?

No. The label fixes the weekday and leaves the hour open, food or no food — and separately confirms that both the hour and the injection site can move with no change to the dose.

5 min read

Burping, Reflux and Gas on a GLP-1: The Label's Widest Gap

Eructation runs under 1% on placebo against 7% on Wegovy — a sevenfold difference, and the widest relative gap in the adverse-reactions table. Reflux is a much smaller increase than people expect.

6 min read

Constipation on a GLP-1: What the Labels Report and What Actually Helps

The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. Here is why it outlasts the nausea, and where the confident advice online runs ahead of the evidence.

6 min read

Where to get tirzepatide (Mounjaro / Zepbound) online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.4

Trimi Health

Knowing which pharmacy fills the vial — it names VialsRx

6.4

ShedRx

Oral orforglipron alongside the injectables

7.5

Synergy Rx

Knowing which pharmacy fills the vial — it names Belmar Pharmacy